Full Press Release Details
– Additional Phase 1b data for ABI-5366, including results from monthly dosing cohort, selected for oral presentation –
– Phase 1b data from ABI-1179 accepted for late-breaker poster presentation –
SOUTH SAN FRANCISCO, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for ABI-5366 and ABI-1179, herpes simplex virus (HSV) helicase-primase inhibitor candidates, will be featured in multiple presentations, including one late-breaker, at the 2026 Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) taking place April 17-21, 2026, in Munich, Germany.
“The selection of ABI-5366 for oral presentation at ESCMID underscores the strength and clinical relevance of the data generated to date, including additional results from the monthly dosing cohort,” said Anuj Gaggar, MD, PhD, chief medical officer of Assembly Bio. “We are also pleased to see the first scientific presentation of Phase 1b data for ABI-1179 recognized as a late-breaker presentation, which highlight its potential as a long-acting therapeutic option for patients with recurrent genital herpes.”
Details of the presentations are as follows:
ABI-5366:
Oral Presentation:ABI-5366-101: a phase 1b study of a novel, oral, long-acting, investigational HSV helicase-primase inhibitor in recurrent genital herpesPresenter:Mark Bloch, MBBS, Momentum Clinical Research and Kirby Institute, University of New South WalesSession Date and Time:April 20, 2026, at 5:30 PM CEST
Poster Presentation:Virologic analyses following treatment with ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor in participants seropositive for HSV-2 with recurrent genital herpesPresenter:Kathryn Kitrinos, PhD, Assembly BioSession Date and Time:April 18, 2026, at 12:00 PM CEST
Poster Presentation:The safety and tolerability of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor in participants with recurrent genital herpesPresenter:Cory Sellwood, MBBS, New Zealand Clinical ResearchSession Date and Time:April 18, 2026, at 12:00 PM CEST
ABI-1179:
Poster Presentation (Late-Breaker):The safety and efficacy of ABI-1179, a novel, oral, long-acting HSV helicase-primase inhibitor for recurrent genital herpes: interim results from a phase 1b studyPresenter:Mark Bloch, MBBS, Momentum Clinical Research and Kirby Institute, University of New South WalesSession Date and Time:April 21, 2026, at 12:00 PM CEST
Assembly Bio intends to make the posters available on the “Events & Presentations” page in the “Investors” section and on the “Publications” page in the “Pipeline” section of its website atwww.assemblybio.com.
ABI-5366 and ABI-1179 are investigational product candidates that have not been approved anywhere globally, and their safety and efficacy have not been established. They are exclusively licensed to Gilead Sciences, Inc. (Gilead) under the collaboration between Assembly Bio and Gilead, and Gilead has the sole right and responsibility for further clinical development and commercialization of these programs.
About Assembly BiosciencesAssembly Biosciences is a biotechnology company dedicated to the development of innovative small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Led by an accomplished team of leaders in virologic drug development, Assembly Bio is committed to improving outcomes for patients struggling with the serious, chronic impacts of herpesvirus, hepatitis B virus (HBV) and hepatitis delta virus (HDV) infections. For more information, visit assemblybio.com.
Forward-Looking StatementsThe information in this press release contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to materially differ. These risks and uncertainties include: Assembly Bio’s ability to realize the potential benefits of its collaboration with Gilead, including all financial aspects of the collaboration and equity investments; Assembly Bio’s ability to initiate and complete clinical studies involving its therapeutic product candidates, including studies contemplated by Assembly Bio’s collaboration with Gilead, in the currently anticipated timeframes or at all; safety and efficacy data from clinical or nonclinical studies may not warrant further development of Assembly Bio’s product candidates; clinical and nonclinical data may not differentiate Assembly Bio’s product candidates from other companies’ candidates; Assembly Bio’s ability to maintain financial resources and secure additional funding necessary to continue its research activities, clinical studies, and other business operations; potential effects of changes in government regulation; results of nonclinical studies may not be representative of disease behavior in a clinical setting and may not be predictive of the outcomes of clinical studies; and other risks identified from time to time in Assembly Bio’s reports filed with the U.S. Securities and Exchange Commission (the SEC). You are urged to consider statements that include the words may, will, would, could, should, might, believes, hopes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comparable words to be uncertain and forward-looking. Assembly Bio intends such forward-looking statements to be covered by the safe harbor provisions contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. More information about Assembly Bio’s risks and uncertainties are more fully detailed under the heading “Risk Factors” in Assembly Bio’s filings with the SEC, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Except as required by law, Assembly Bio assumes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.